<DOC>
	<DOCNO>NCT01501747</DOCNO>
	<brief_summary>The total effect medication sum drug effect , placebo effect ( mean response placebo ) , interaction . Current interpretation clinical trial ( gold standard evidence-based-medicine ) assume interaction , mechanism ( ) underlie interaction fully explore . One possibility placebo effect may modulate drug bioavailability . Using caffeine model drug , recently show placebo effect caffeine ingestion prolongs caffeine half life . Due novelty find important clinical practice clinical research implication , need confirm another set subject extended additional drug . The result study expect understanding mechanism action widely use medical intervention , i.e. , placebo . The result important clinical practice clinical research .</brief_summary>
	<brief_title>The Placebo Effect May Involve Modulating Drug Bioavailability</brief_title>
	<detailed_description>The total effect medication sum drug effect , placebo effect ( mean response placebo ) , interaction . Current interpretation clinical trial ( gold standard evidence-based-medicine ) assume interaction , mechanism ( ) underlie interaction fully explore . One possibility placebo effect may modulate drug bioavailability . Using caffeine model drug , recently show placebo effect caffeine ingestion prolongs caffeine half life . Due novelty find important clinical practice clinical research implication , need confirm another set subject extended additional drug . DESIGN : Balanced cross-over , single-dose , two-period , two-group deign compare caffeine , paracetamol , cephalexin , ibuprofen describe ( overt ) medication describe placebo ( covert ) . METHODS : 32 , 50 , 50 , 30 healthy adult volunteer enrol caffeine ( 300 mg ) , paracetamol ( 500 mg ) , cephalexin ( 500 mg ) , ibuprofen ( 400 mg ) cross-over study , respectively . Volunteers partially deceive intervention assignment ( i.e. , covert arm ) . Serum level drug blindly determine locally validate HPLC assay . Plasma half life ( primary outcome ) well Cmax , Tmax , AUC ( secondary outcome ) drug determine analyzed ANOVA .</detailed_description>
	<mesh_term>Acetaminophen</mesh_term>
	<mesh_term>Ibuprofen</mesh_term>
	<mesh_term>Caffeine</mesh_term>
	<mesh_term>Cephalexin</mesh_term>
	<criteria>Having evidence clinically important deviation normal health indicate medical history , vital sign , clinical laboratory test . Acceptance abstain take medication birth control pill ( include overthecounter drug ) least 1 week prior , study ; smoke take alcohol caffeine relate xanthenescontaining beverage food 48 hour throughout study period . Having good peripheral venous access . For caffeine study , habitual daily caffeine intake 100300 mg. Women nonpregnant nonlactating . For menstruate woman , study conduct 5 19 day last menstrual period urine pregnancy test perform . Should history hypersensitivity drug test related compound . Body Mass Index ( BMI ) less 35 kg/m2 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Placebo effect</keyword>
	<keyword>drug half life</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>